Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference
Rhea-AI Summary
Celcuity (Nasdaq: CELC) will present at the 8th Annual Evercore Healthcare Conference in Miami, Florida on December 2-4, 2025. CEO and co-founder Brian Sullivan is scheduled for a fireside chat at 7:30 a.m. ET on December 3, 2025. A live webcast will be available at https://wsw.com/webcast/evercore52/celc/2320846 and from the company's investor events page at https://ir.celcuity.com/events-presentations/, with a replay posted shortly after.
Positive
- None.
Negative
- None.
News Market Reaction – CELC
In the Nov 26 session, CELC gained 1.28%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 26 | Clinical data update | Positive | +0.8% | Updated Phase 3 VIKTORIA‑1 PIK3CA wild-type cohort data accepted for SABCS. |
| Nov 26 | Conference appearance | Neutral | +1.3% | Announcement of participation and fireside chat at Evercore healthcare conference. |
| Nov 17 | NDA submission | Positive | -0.5% | Completion of NDA submission to FDA for gedatolisib in advanced breast cancer. |
| Nov 12 | Earnings & clinical | Positive | +7.6% | Q3 2025 financials plus detailed positive Phase 3 VIKTORIA‑1 results and pipeline update. |
| Nov 05 | Earnings scheduling | Neutral | +2.2% | Scheduling of Q3 2025 results release and related webcast and call details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has generally coincided with positive price reactions, with one divergence where a clinically positive NDA submission was followed by a modest decline.
Over recent months, Celcuity reported multiple late-stage clinical milestones and corporate updates. A Q3 2025 earnings and clinical update on Nov 12, 2025 saw a 7.56% move, while completion of the gedatolisib NDA on Nov 17, 2025 was followed by a small decline. Conference- and presentation-related items on Nov 5, Nov 26, and updated VIKTORIA‑1 data at SABCS also produced modest positive moves. Today’s Evercore conference appearance fits this pattern of event-driven visibility news alongside major clinical and regulatory progress.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the 8th Annual Evercore Healthcare Conference to be held in Miami, Florida on December 2-4, 2025.
Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, is scheduled for a fireside chat at 7:30 a.m. ET on Wednesday, December 3, 2025. A live webcast of the event will be available using this weblink https://wsw.com/webcast/evercore52/celc/2320846. Alternatively, the live webcast will be accessible from the Investors section of the company's website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after.
About Celcuity
Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTor (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- ABC has completed enrollment and the company has reported detailed results for the PIK3CA wild-type cohort, and has completed enrollment of patients for the PIK3CA mutant cohort. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- ABC is currently enrolling patients. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X.
View source version of release on GlobeNewswire.com
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123
ICR Healthcare
Patti Bank, patti.bank@icrhealthcare.com
(415) 513-1284
